
Sanofi accuses MSD of US patent infringement
pharmafile | September 19, 2016 | News story | Sales and Marketing | MSD, Sanofi, lawsuit
Sanofi has filed a suit against MSD in the United States District Court for the District of Delaware accusing the US firm of infringing ten of its patents.
This move comes after a notification that MSD has filed a New Drug Application with the FDA for an insulin glargine drug product; the company asserts that its NDA included a paragraph IV certification challenging all of the ten patents listed in the FDA Orange Book for Sanofi’s Lantus and Lantus SoloStar products.
Matt Fellows
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …






